Maintenance Of Clinical Response And Remission In Adults With Moderately To Severely Active Crohn S Disease — Patent Landscape
1
Approved drugs
9
Active US patents
54/100
Avg vulnerability
—
Annual revenue covered
Originators in Maintenance Of Clinical Response And Remission In Adults With Moderately To Severely Active Crohn S Disease
Cliff calendar — next 15 years
1
29
1
30
7
36
Approved drugs ranked by patent estate
| Drug | Originator | Active patents | Avg vuln | Revenue | First cliff |
|---|---|---|---|---|---|
|
Velsipity
Etrasimod Arginine
|
Pfizer Inc. | 9 | 54 | — | 2029-07-22 |
Most attackable patents
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 9126932 | Velsipity | method of use | 76 | 2029-07-22 |
| 12156866 | Velsipity | method of use | 75 | 2036-01-06 |
| 12377071 | Velsipity | method of use | 75 | 2036-01-06 |
| 11884626 | Velsipity | method of use | 75 | 2036-06-21 |
| 11007175 | Velsipity | method of use | 70 | 2036-01-06 |
| 10676435 | Velsipity | method of use | 70 | 2036-06-21 |
| 8580841 | Velsipity | composition of matter | 18 | 2030-03-05 |
| 11091435 | Velsipity | composition of matter | 12 | 2036-06-21 |
| 10301262 | Velsipity | composition of matter | 12 | 2036-06-21 |
Strongest defences
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 11091435 | Velsipity | composition of matter | 12 | 2036-06-21 |
| 10301262 | Velsipity | composition of matter | 12 | 2036-06-21 |
| 8580841 | Velsipity | composition of matter | 18 | 2030-03-05 |
| 10676435 | Velsipity | method of use | 70 | 2036-06-21 |
| 11007175 | Velsipity | method of use | 70 | 2036-01-06 |
| 11884626 | Velsipity | method of use | 75 | 2036-06-21 |
| 12156866 | Velsipity | method of use | 75 | 2036-01-06 |
| 12377071 | Velsipity | method of use | 75 | 2036-01-06 |
| 9126932 | Velsipity | method of use | 76 | 2029-07-22 |
Related
- Maintenance Of Clinical Response And Remission In Adults With Moderately To Severely Active Crohn S Disease — full disease profile
- AI Patent Landscape Report — type "maintenance of clinical response and remission in adults with moderately to severely active crohn s disease" for an AI exec memo
- Company Patent Rankings
- Biosimilar Opportunity Scanner